Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein

Anshuman Dixit1, Ali Torkamani, Nicholas J Schork

  • 1Center for Bioinformatics, The University of Kansas, Lawrence, Kansas, USA.

Biophysical Journal
|February 3, 2009
PubMed

Insights

Cancer mutations in RET and MET kinases destabilize their inactive state, promoting activation. This molecular mechanism, involving altered dynamics and stability, explains oncogene addiction and drug resistance in cancer therapies.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Computational Biology

Background:

  • Protein kinases like RET and MET are crucial in human cancer, often driven by mutations causing oncogene addiction.
  • Understanding kinase activation mechanisms is key to developing targeted cancer therapies.

Purpose of the Study:

  • To investigate the molecular mechanism of activation for RET and MET kinases harboring cancer mutations.
  • To quantify how mutations alter protein kinase structure, dynamics, and stability.
  • To explore the impact of mutations on inhibitor binding and drug resistance.

Main Methods:

  • Structural modeling
  • Molecular dynamics simulations
  • Free energy simulations
  • Circular dichroism spectroscopy
  • Differential scanning calorimetry

Main Results:

  • Cancer mutations significantly destabilize the inactive kinase state, shifting the equilibrium towards the active form.
  • Mutations increase local mobility and conformational entropy, but enthalpy loss decreases overall thermodynamic stability.
  • Computed stability changes correlate with experimental data (CD, DSC).
  • Simulations explain differential inhibitor binding to wild-type vs. mutant kinases, consistent with observed drug resistance.

Conclusions:

  • Activating cancer mutations in RET and MET kinases function by destabilizing the inactive conformation.
  • This destabilization creates a dynamic imbalance favoring the active enzyme state.
  • A similar activation mechanism is suggested for RET and MET mutations, with higher oncogenic activity correlating with greater destabilization.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...